Psychiatric decision making in the adoption of a new antipsychotic in Germany

Psychiatric Services

Volumn 57, Issue 5, 2006, Pages 700-703

  Hamann, Johannes ^a   Adjan, Susanne ^a   Leucht, Stefan ^a   Kissling, Werner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GERMANY; HEALTH CARE QUALITY; HUMAN; HUMAN EXPERIMENT; MALE; MEDICAL DECISION MAKING; MENTAL DISEASE; NORMAL HUMAN; PHYSICIAN; PRESCRIPTION; PROSPECTIVE STUDY; SCHIZOPHRENIA;

EID: 33646440885     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.2006.57.5.700     Document Type: Article

References (12)

1. Haines A, Jones R: Implementing findings of research. British Medical Journal 308: 1488-1492, 1994
2. Solomon DH, Schneeweiss S, Glynn RJ, et al: Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? American Journal of Medicine 115:715-720, 2003
3. Steffensen FH, Sorensen HT, Olesen F: Diffusion of new drugs in Danish general practice. Family Practice 16:407-413, 1999
4. Tamblyn R, McLeod P, Hanley JA, et al: Physician and practice characteristics associated with the early utilization of new prescription drugs. Medical Care 41:895-908, 2003
5. Woodward ND, Purdon SE, Meltzer HY, et al: A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology 8:457-472, 2005
6. Leucht S, Pitschel-Walz G, Abraham D, et al: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophrenia Research 35:51-68, 1999
7. Leucht S, Wahlbeck K, Hamann J, et al: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581-1589, 2003
8. Rosenheck R, Perlick D, Bingham S, et al: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290:2693-2702, 2003
9. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005
10. Galanter CA, Patel VL: Medical decision making: a selective review for child psychiatrists and psychologists. Journal of Child Psychology and Psychiatry 46:675-689, 2005
11. Dalbert C: Die Ungewissheitstoleranzskala: Skaleneigenschaften und Validierungsbefunde [The Uncertainty Tolerance Scale: Properties and Validation]. Halle, Germany, Martin-Luther-Universität Halle-Wittenberg, 1999
12. Hamann J, Langer B, Leucht S, et al: Medical decision making in antipsychotic drug choice for schizophrenia. American Journal of Psychiatry 161:1301-1304, 2004